Madrigal Pharmaceuticals Says Findings Consistent With Established Rezdiffra Safety Profile

Nov 5 (Reuters) - Madrigal Pharmaceuticals, Inc. MDGL.O:

• MADRIGAL PHARMACEUTICALS - UP TO 93% OF PATIENTS IMPROVED OR STABILIZED LIVER STIFFNESS AT ONE YEAR WITH REZDIFFRA

• MADRIGAL PHARMACEUTICALS - UP TO 72% OF PATIENTS REMAINED ON REZDIFFRA AT ONE YEAR WITH HIGH ADHERENCE

• MADRIGAL PHARMACEUTICALS - SAFETY FINDINGS CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF REZDIFFRA

• MADRIGAL PHARMACEUTICALS - IMPROVEMENTS IN LIVER HEALTH OBSERVED REGARDLESS OF GLP-1 USE; UP TO 53% RECEIVED GLP-1

• MADRIGAL PHARMACEUTICALS - 11% EXPERIENCED ≥1 ADVERSE EVENT; DIARRHEA 7%, NAUSEA 4%, PRURITUS 2%, VOMITING 2%, FATIGUE ≤1%

Further company coverage: MDGL.O